DavidHoldenHenryIIIMD
Oncology • Philadelphia, PAHematologic Oncology
Clinical Professor of Medicine, University Pennsylvania
Dr. Henry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
230 W Washington Sq
Philadelphia, PA 19106Phone+1 215-829-6088Fax+1 215-829-6104
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1978 - 1981- University of Pennsylvania Health SystemResidency, Internal Medicine, 1975 - 1977
Perelman School of Medicine at the University of PennsylvaniaClass of 1975
Certifications & Licensure
PA State Medical License 1976 - 2024
FL State Medical License 2015 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2011-2014
- Philadelphia Magazine Castle Connolly, 2006, 2010-2014
- America's Top Doctors for Cancer Castle Connolly, 2010-2013
Clinical Trials
- Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
- Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma Start of enrollment: 2009 Aug 01
- Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Start of enrollment: 2010 Aug 27
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsRoxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial.Moshe Mittelman, David H Henry, John A Glaspy, Anil Tombak, Rosemary Harrup
American Journal of Hematology. 2024-09-01 - 8 citationsBrentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.Paul G Rubinstein, Page C Moore, Milan Bimali, Jeanette Y Lee, Michelle A Rudek
The Lancet. Haematology. 2023-08-01 - 5 citationsOpen-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies.John Glaspy, Nashat Y Gabrail, Patricia Locantore-Ford, Tyson Lee, Katharina Modelska
American Journal of Hematology. 2023-05-01
Abstracts/Posters
- Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's LymphomaDavid H. Henry, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Efficacy and Safety of Ferric Carboxymaltose Injection in Reducing Anemia in Patients Receiving Chemotherapy for Non-Myeloid Malignancies: A Phase 3, Placebo-Controlle...David H. Henry, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085David H. Henry, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Concerns for Clinicians over 65 Grow in the Face of COVID-19April 9th, 2020
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
